CLDX

Celldex Therapeutics, Inc. (CLDX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Form 10-Q for the quarterly period ended June 30, 2026. Celldex Therapeutics is a biopharmaceutical company focused on developing antibody-based treatments for allergic, inflammatory, and autoimmune disorders. The company's primary asset is barzolvolimab (CDX-0159), a monoclonal antibody targeting the KIT receptor, currently in Phase 3 development for Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has a bispecific antibody platform with lead candidate CDX-622.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 97% year-over-year for the six months ended June 30, 2026. This was primarily due to a significant reduction in contract and grant revenue from Rockefeller University ($0.030 million vs. $1.367 million in the prior year).
• Increased Net Loss: Net loss increased by 38% year-over-year to $152.2 million. The increase was driven by higher Research and Development (R&D) expenses, specifically related to the barzolvolimab clinical trials.
• R&D Expense Growth: R&D expenses rose 32% year-over-year to $140.5 million. Product development costs increased by $26.2 million, attributed to expanded clinical trial activities and contract manufacturing for barzolvolimab.
• Capital Raise: In April 2026, the company completed an underwritten public offering of 11.9 million shares, generating net proceeds of $323.8 million. This significantly bolstered liquidity compared to the prior period.

Outlook, Management Commentary, and Risks

• Clinical Milestones:
  • CSU Phase 3: Enrollment of 1,939 patients is complete. Topline data is expected in September/October 2026. A Biologics License Application (BLA) is planned for 2027 if data is positive.
  • CIndU Phase 3: Initiated in December 2025; enrollment is ongoing.
  • Prurigo Nodularis (PN): The Phase 2 study failed to meet primary or key secondary endpoints. The company is discontinuing this program, noting that mast cells may not be the primary driver in PN.
  • Atopic Dermatitis (AD): Phase 2 enrollment completed in January 2026; topline data expected in late 2026.
  • CDX-622: Phase 1 data presented in June 2026 showed the bispecific antibody was well-tolerated and induced mast cell depletion. A Phase 1 proof-of-mechanism study in asthma was initiated in January 2026.
• Liquidity: Management believes current cash and marketable securities ($717.6 million) are sufficient to fund operations through 2028. However, future funding may be required depending on the timing of a potential $52.5 million milestone payment related to the Kolltan acquisition settlement, which could be paid in cash or stock.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the potential need for additional capital on unfavorable terms, and the possibility of delaying or discontinuing programs if funding is insufficient. The company also faces risks related to the Kolltan milestone payment obligations.

Investor Verification Checklist

• Verify the timeline and expectations for the barzolvolimab Phase 3 topline data (expected Sept/Oct 2026) and the subsequent BLA filing in 2027.
• Confirm the status of the Prurigo Nodularis (PN) program discontinuation and any potential impact on the overall R&D budget allocation.
• Review the terms of the Kolltan Settlement Agreement regarding the $52.5 million regulatory approval milestone and the company's election to pay in cash vs. stock.
• Monitor the CDX-622 Phase 1 data in asthma and the progression of the bispecific platform pipeline.
• Assess the sustainability of the cash burn rate (~$123 million in operating cash used for the first half of 2026) against the current cash runway.